Literature DB >> 10201898

Factors associated with the development of neonatal tolerance after the administration of a plasmid DNA vaccine.

M Ichino1, G Mor, J Conover, W R Weiss, M Takeno, K J Ishii, D M Klinman.   

Abstract

A plasmid DNA vaccine encoding the circumsporozoite protein of malaria (pCSP) induces tolerance rather than immunity when administered to newborn mice. We find that this tolerance persists for >1 yr after neonatal pCSP administration and interferes with the induction of protective immunity in animals challenged with live sporozoites. Susceptibility to tolerance induction wanes rapidly with age, disappearing within 1 wk of birth. Higher doses of plasmid are more tolerogenic, and susceptibility to tolerance is not MHC-restricted. CD8+ T cells from tolerant mice suppress the in vitro Ag-specific immune response of cells from adult mice immunized with pCSP. Similarly, CD8+ T cells from tolerant mice transfer nonresponsiveness to naive syngeneic recipients. These findings clarify the cellular basis and factors contributing to the development of DNA vaccine-induced neonatal tolerance.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10201898

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Immune responses following neonatal DNA vaccination are long-lived, abundant, and qualitatively similar to those induced by conventional immunization.

Authors:  D E Hassett; J Zhang; M Slifka; J L Whitton
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

Review 2.  Plasmid DNA vaccines. Immunology, tolerance, and autoimmunity.

Authors:  G Mor; M Eliza
Journal:  Mol Biotechnol       Date:  2001-11       Impact factor: 2.695

3.  Co-delivery of indoleamine 2,3-dioxygenase prevents loss of expression of an antigenic transgene in dystrophic mouse muscles.

Authors:  D Sharma; R Al-Khalidi; S Edgar; Q An; Y Wang; C Young; D Nowis; D C Gorecki
Journal:  Gene Ther       Date:  2016-12-22       Impact factor: 5.250

Review 4.  FDA guidance on prophylactic DNA vaccines: analysis and recommendations.

Authors:  Dennis M Klinman; Sven Klaschik; Debra Tross; Hidekazu Shirota; Folkert Steinhagen
Journal:  Vaccine       Date:  2009-11-24       Impact factor: 3.641

Review 5.  The notorious R.N.A. in the spotlight - drug or target for the treatment of disease.

Authors:  Philipp Reautschnig; Paul Vogel; Thorsten Stafforst
Journal:  RNA Biol       Date:  2016-07-14       Impact factor: 4.652

Review 6.  DNA vaccine.

Authors:  Zhengrong Cui
Journal:  Adv Genet       Date:  2005       Impact factor: 1.944

Review 7.  Transplacental Gene Delivery (TPGD) as a Noninvasive Tool for Fetal Gene Manipulation in Mice.

Authors:  Shingo Nakamura; Satoshi Watanabe; Naoko Ando; Masayuki Ishihara; Masahiro Sato
Journal:  Int J Mol Sci       Date:  2019-11-25       Impact factor: 5.923

8.  Detection of Progeny Immune Responses after Intravenous Administration of DNA Vaccine to Pregnant Mice.

Authors:  Ke-Qin Xin; Shin Sasaki; Yoshitsugu Kojima; Nao Jounai; Yasuko Kumamoto; Kumiko Hashimoto; Kaori Shinoda; Kenji Hamajima; Kenji Okuda
Journal:  Biol Proced Online       Date:  2002-04-23       Impact factor: 3.244

9.  Delayed maturation of an IL-12-producing dendritic cell subset explains the early Th2 bias in neonatal immunity.

Authors:  Hyun-Hee Lee; Christine M Hoeman; John C Hardaway; F Betul Guloglu; Jason S Ellis; Renu Jain; Rohit Divekar; Danielle M Tartar; Cara L Haymaker; Habib Zaghouani
Journal:  J Exp Med       Date:  2008-09-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.